An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

The bioequivalence of two formulations of desmopressin (dDAVP), a vasopressin analogue prescribed for nocturnal enuresis treatment in children, has been previously confirmed in adults but not in children.

This trial has been registered at www.clinicaltrials.gov (identifier NCT02584231; EudraCT 2014-005200-13).

Who Took Part

PubMed indexes the participants as infants, young children, children and teenagers, both men and women.

Previously published data from one PK study and one PK/PD study in children aged between 6 and 16 years were combined with a new PK/PD study in children aged between 6 months and 8 years, and analysed using population PK/PD modelling.

How the Study Was Run

In design terms this was a randomized and double-blind study.

The participants were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vasopressin.

What Was Measured

Topics PubMed links to this paper include Antidiuretic Agents, Biological Availability, Computer Simulation, Deamino Arginine Vasopressin, Drug Compounding, Fasting and Models, Biological.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vasopressin and Desmopressin.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Clinical pharmacokinetics), a journal based in Switzerland.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.